Last reviewed · How we verify

CR-CSSS Champlain-Charles-Le Moyne — Portfolio Competitive Intelligence Brief

CR-CSSS Champlain-Charles-Le Moyne pipeline: 2 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
aflibercept + FOLFIRI aflibercept + FOLFIRI marketed VEGF inhibitor (fusion protein) + chemotherapy combination VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component) Oncology
Piperacillin-tazobactam administered in a standard infusion Piperacillin-tazobactam administered in a standard infusion marketed
Zyprexa® (OLANZapine 5MG) Zyprexa® (OLANZapine 5MG) phase 3 atypical antipsychotic D2 receptor, 5-HT2A receptor Psychiatry
Emend® (Aprepitant) Emend® (Aprepitant) phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. CCTU · 1 shared drug class
  3. Eli Lilly and Company · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Hôpital Franco-Britannique-Fondation Cognacq-Jay · 1 shared drug class
  6. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. Acacia Pharma Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CR-CSSS Champlain-Charles-Le Moyne:

Cite this brief

Drug Landscape (2026). CR-CSSS Champlain-Charles-Le Moyne — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cr-csss-champlain-charles-le-moyne. Accessed 2026-05-16.

Related